Previous 10 | Next 10 |
2024-06-08 07:25:00 ET On June 2, Intellia Therapeutics ' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors sa...
2024-06-05 07:11:15 ET Summary Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust t...
2024-06-04 17:30:03 ET Citigroup analyst issues UNDERPERFORM recommendation for NTLA on June 4, 2024 04:00PM ET. The previous analyst recommendation was Underperform. NTLA was trading at $23.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-04 17:30:03 ET Wedbush analyst issues NEUTRAL recommendation for NTLA on June 4, 2024 04:00PM ET. The previous analyst recommendation was Neutral. NTLA was trading at $23.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2024-06-03 14:32:19 ET Summary Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200...
2024-06-03 14:14:05 ET Summary BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently. The company's primary drug candidate, Acoramidis, has a marketing application accepted by the FDA for ...
2024-06-03 10:32:00 ET Read the full article on Seeking Alpha For further details see: Intellia rallies on Phase 1 data for CRISPR-based HAE therapy
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE) Eight of 10 patients remain completely attack-free following the 16-week primary observation per...
2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-07-23 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...